United States · FDA National Drug Code directory
NAGLAZYME
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 68135-020_02482a8a-8333-4e9c-a9dc-ff7780f40363
- Product NDC
- 68135-020
- Form
- SOLUTION
- Composition / generic term
- galsulfase
- Labeler
- BioMarin Pharmaceutical Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20050609
- Source listing expiry
- 20261231
Source-listed ingredients
- GALSULFASE — 5 mg/5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL in 1 CARTON (68135-020-01) / 5 mL in 1 VIAL · 68135-020-01
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →